Pro Medicus Ltd

Pro Medicus lands a 7‑year, AUD 25 m U.S. contract with BayCare, launching its cloud‑based Visage 7 imaging platform and boosting North American revenue.

Pro Medicus’s 2024 surge: $95.6M revenue, AI‑driven Visage 7 cloud contracts, margin gains, and regulatory hurdles – a detailed look at the upside and risks.

Pro Medicus Ltd, an Australian health-tech provider, has secured a €10 million, five-year contract with University Hospital Heidelberg and the German Cancer Research Institute, marking a significant expansion into the European market and positioni…

Pro Medicus Ltd, a health technology company, is facing market headwinds, including a decline in share price, but remains committed to its mission of revolutionizing healthcare through innovative technology.

Pro Medicus Ltd has reported record growth in its latest earnings report, with a 52-week high stock price of 336 AUD and a strong correlation between its stock price and underlying financial performance.

Pro Medicus Ltd has reported record growth in its FY 2025 earnings, driven by revenue increases, market expansion, and product innovation, solidifying its position as a leading player in the healthcare technology sector.

Pro Medicus Ltd has reported record growth and strong valuation multiples in its latest earnings report, solidifying its position as a leading player in the healthcare technology sector.

Pro Medicus secures a $10 million investment from 4DMedical, but its ability to sustain momentum and deliver returns for investors remains uncertain.

Pro Medicus Ltd’s stock price has surged 42% following a major investment, boosting the company’s market value and paving the way for growth through a new partnership with 4DMedical.

Pro Medicus Ltd’s stock price has surged 42% following a $10 million investment in medical imaging company 4DMedical.